,51 In September 2024, the Oncologic Drugs Advisory Committee voted against the use of checkpoint inhibitors in HER2-negative gastric/GEJ adenocarcinoma with PD-L1 expression less than 1 based on pooled analysis done by the FDA showing lack of benefit in this patient population.52 The gene discussed is CD274; the disease is gastroesophageal junction adenocarcinoma.